Published: July 27, 2022 19:13:45 | Updated: August 31, 2022 19:27:57
Pfizer Inc and its German partner BioNTech SE said on Wednesday they started a mid-stage study of a modified COVID-19 vaccine which targets both the original as well as the BA.2 omicron subvariant.
Pfizer said the vaccine is in an initial proof-of-concept study to gather more data, reports Reuters.
Together, the BA.4 and BA.5 subvariants are estimated to make up nearly 95 per cent of the circulating coronavirus variants in the United States for the week ended Jul 23.
Moderna to make milestone payments to US for Covid-19 vaccine
Bird flu situation 'worrying', WHO working with Cambodia
A woman dies every two minutes due to pregnancy or childbirth: UN report
Oral dose of azithromycin at normal birth can reduce 33pc maternal sepsis and deaths: Study
Can topical treatment alone fix acne scars?
Vitamin A-plus campaign for 22.0 million children held
Why the success of making an artificial heart remains elusive?
No specific research on zinc level in rice
© 2024 - All Rights with The Financial Express
